Viral Cardiovascular Injury as a Potential Modifier of Cancer Therapy–Related Cardiotoxicity: A Pharmacovirological Review
Acta Poloniae Pharmaceutica - Drug Research · 17.07.2026 · 84 (2) · 155-165
DOI: 10.32383/appdr/224735 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Poloniae Pharmaceutica - Drug Research, online erschienen am 17.07.2026. Verfasst von Guoqiang Xing und 2 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Cardiovascular toxicity is one of the greatest challenges for modern oncology, since it affects patients receiving anthracycline, HER2, TKI, and ICI therapy. The agents can cause myocardial dysfunction, damage to blood vessels, arrhythmia, and cardiomyocytes’ inflammation in an immunologically dependent manner. Alongside, numerous viral infections such as SARS-CoV-2, HIV, CMV, enteroviruses, adenoviruses, EBV, influenza viruses, and Parvovirus B19 have been linked to endothelial dysfunction, myocarditis, thrombo-inflammation, and chronic cardiovascular susceptibility. This review examines whether viral cardiovascular injury may act as a clinically relevant modifier of cancer therapy–related cardiotoxicity. Evidence from current literature supports mechanistic overlap between infection-associated inflammation and anticancer drug-induced cardiac stress; however, direct clinical proof of defined virus–drug cardiotoxic synergy remains limited. The strongest support currently lies in the biological plausibility that prior viral myocarditis, endothelial injury, or chronic immune activation may reduce cardiovascular reserve in selected patients receiving cardiotoxic cancer therapy. A pharmacovirological framework may therefore help generate focused research questions for cardio-oncology, particularly through integrated evaluation of virological history, cardiovascular biomarkers, imaging, and therapy-specific toxicity profiles. Prospective studies are needed to determine when viral factors become clinically actionable determinants of cardiovascular risk during cancer treatment.
Zitieren
APA
Xing, G., Lei, X., & Shao, D. (2026). Viral Cardiovascular Injury as a Potential Modifier of Cancer Therapy–Related Cardiotoxicity: A Pharmacovirological Review. Acta Poloniae Pharmaceutica - Drug Research, 84(2), 155-165. https://doi.org/10.32383/appdr/224735
Vancouver
Xing G, Lei X, Shao D. Viral Cardiovascular Injury as a Potential Modifier of Cancer Therapy–Related Cardiotoxicity: A Pharmacovirological Review. Acta Poloniae Pharmaceutica - Drug Research. 2026;84(2):155-165. doi:10.32383/appdr/224735
BibTeX
@article{Xing2026,
author = {Xing, Guoqiang and Lei, Xinjuan and Shao, Danyang},
title = {Viral Cardiovascular Injury as a Potential Modifier of Cancer Therapy–Related Cardiotoxicity: A Pharmacovirological Review},
journal = {Acta Poloniae Pharmaceutica - Drug Research},
year = {2026},
volume = {84},
number = {2},
pages = {155--165},
doi = {10.32383/appdr/224735}
}
EUVIMED